CoChat

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy

Open access

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Despite treatment with statins, dyslipidaemia patients with elevated cholesterol- and triglyceride-levels remain at high residual risk for major adverse cardiovascular events (MACE). New lipid-lowering drugs must prevent the occurrence of MACE and exhibit cost-effectiveness for their successful adoption to clinical practice. OBJECTIVE: To assess the cost effectiveness of icosapent ethyl, fenofibrate, ezetimibe, evolocumab, and alirocumab in combination with statins compared to statin monotherapy for cardiovascular prevention from the perspective of UK's National Health Service. METHODS: A Markov model simulated the progression of cardiovascular disease and MACE, including myocardial infarction, stroke, angina pectoris, and coronary revascularisation, in dyslipidaemia patients. The model was populated with cardiovascular outcome trial data for each drug. Cost and utility data were extracted from peer-reviewed literature. The incremental cost-effectiveness ratio (ICER) is reported per quality-adjusted life years (QALY) gained in 2021 Great Britain Pounds (£). RESULTS: For primary cardiovascular prevention, icosapent ethyl increased QALYs by 0.79 and costs by £15,421 compared to statin monotherapy (ICER = £19,485/QALY). Fenofibrate yielded 0.62 additional QALYs at cost-savings of - £6127 (ICER = - £9932/QALY). For secondary prevention, the omega-3 fatty acid icosapent ethyl extended QALYs by 0.98 at costs of £12,981 compared to statin monotherapy (ICER = £13,285/QALY). Fenofibrate added 0.85 QALYs whilst saving - £637 (ICER = - £7472/QALY). Ezetimibe increased QALYs by 0.60 at cost reductions of - £2529 (ICER = - £4231/QALY). PCSK9 inhibitors provided QALYs of 0.53 and 0.86 at costs of £45,279 and £46,375 for evolocumab (ICER = £85,193/QALY) and alirocumab (ICER = £54,211/QALY), respectively. At a willingness-to-pay threshold of £25,000/QALY, there is a probability of 100% for icosapent ethyl (98% in primary prevention) and 0% for PCSK9 inhibitors to be cost effective in secondary prevention. CONCLUSIONS: Icosapent ethyl is cost effective for primary and secondary cardiovascular prevention at an annual price of £2064 in the UK. For PCSK9 inhibitors, price discounts or prescription restrictions are necessary to achieve cost effectiveness.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40261-022-01173-3

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Markov model structure of cardiovascular diseases progression and acute events. Patients commence the model in the “Alive without CVD” (primary prevention) or “Alive with CVD” (secondary prevention) state. Every year patients were at risk of experiencing acute cardiovascular events (myocardial infarction, stroke, coronary revascularisation, unstable angina pectoris) and dying from CVD or non-CVD causes. Model structure adopted from Michaeli et al. [23]. CVD cardiovascular disease
Fig. 1 Markov model structure of cardiovascular diseases progression and acute events. Patients commence the model in the “Alive without CVD” (primary prevention) or “Alive with CVD” (secondary prevention) state. Every year patients were at risk of experiencing acute cardiovascular events (myocardial infarction, stroke, coronary revascularisation, unstable angina pectoris) and dying from CVD or non-CVD causes. Model structure adopted from Michaeli et al. [23]. CVD cardiovascular diseaseCC BY-NC · PubMed Central
Fig. 2 Cost-effectiveness plane for ezetimibe, evolocumab, alirocumab, icosapent ethyl, and fenofibrate in combination with statins for primary (A) and secondary (B) cardiovascular prevention. QALYs and costs presented for the average person simulated in the model. Lipid-lowering drugs are presented as cholesterol-and triglyceride-lowering according to guideline recommendations [11]. Costs in 2021 Great Britain Pounds (£). QALY quality-adjusted life year
Fig. 2 Cost-effectiveness plane for ezetimibe, evolocumab, alirocumab, icosapent ethyl, and fenofibrate in combination with statins for primary (A) and secondary (B) cardiovascular prevention. QALYs and costs presented for the average person simulated in the model. Lipid-lowering drugs are presented as cholesterol-and triglyceride-lowering according to guideline recommendations [11]. Costs in 2021 Great Britain Pounds (£). QALY quality-adjusted life yearCC BY-NC · PubMed Central
Fig. 3 Probabilistic sensitivity analysis for ezetimibe, evolocumab, alirocumab, icosapent ethyl, and fenofibrate in combination with statins for primary (A) and secondary (B) cardiovascular prevention. Input parameters displayed in Table 1 were varied by their confidence intervals and distribution; 1000 simulations of this probabilistic sensitivity analysis are visualised in this Figure. The grey line illustrates the English NHS’ upper willingness-to-pay threshold of £30,000 per QALY. Lipid-lowering drugs are presented as cholesterol- and triglyceride-lowering according to guideline recommendations [11]. QALYs and costs presented for the average person simulated in the model. Costs in 2021 Great Britain Pounds (£). ICER incremental cost-effectiveness ratio, NHS National Health Service, QALY quality-adjusted life year
Fig. 3 Probabilistic sensitivity analysis for ezetimibe, evolocumab, alirocumab, icosapent ethyl, and fenofibrate in combination with statins for primary (A) and secondary (B) cardiovascular prevention. Input parameters displayed in Table 1 were varied by their confidence intervals and distribution; 1000 simulations of this probabilistic sensitivity analysis are visualised in this Figure. The grey line illustrates the English NHS’ upper willingness-to-pay threshold of £30,000 per QALY. Lipid-lowering drugs are presented as cholesterol- and triglyceride-lowering according to guideline recommendations [11]. QALYs and costs presented for the average person simulated in the model. Costs in 2021 Great Britain Pounds (£). ICER incremental cost-effectiveness ratio, NHS National Health Service, QALY quality-adjusted life yearCC BY-NC · PubMed Central
Fig. 4 Probability of cost effectiveness at different willingness-to-pay thresholds for ezetimibe, evolocumab, alirocumab, icosapent ethyl, and fenofibrate in combination with statins for primary (A) and secondary (B) cardiovascular prevention. The grey line illustrates the English NHS’ upper willingness-to-pay threshold of £30,000 per QALY. Dotted lines show the willingness-to-pay thresholds at which the probability of cost-effectiveness surpasses 95%. Lipid-lowering drugs are presented as cholesterol-and triglyceride-lowering according to guideline recommendations [11]. QALYs and costs presented for the average person simulated in the model. Costs in 2021 Great Britain Pounds (£) and willingness-to-pay thresholds in £/QALY. NHS National Health Service, QALY quality-adjusted life year
Fig. 4 Probability of cost effectiveness at different willingness-to-pay thresholds for ezetimibe, evolocumab, alirocumab, icosapent ethyl, and fenofibrate in combination with statins for primary (A) and secondary (B) cardiovascular prevention. The grey line illustrates the English NHS’ upper willingness-to-pay threshold of £30,000 per QALY. Dotted lines show the willingness-to-pay thresholds at which the probability of cost-effectiveness surpasses 95%. Lipid-lowering drugs are presented as cholesterol-and triglyceride-lowering according to guideline recommendations [11]. QALYs and costs presented for the average person simulated in the model. Costs in 2021 Great Britain Pounds (£) and willingness-to-pay thresholds in £/QALY. NHS National Health Service, QALY quality-adjusted life yearCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Research works printed but not linked: 3

  1. Ollendorf DA, McQueen RB, Campbell JD, Synnott PG, Herron-Smith S, Fazioli K, et al. Additive therapies for cardiovascular disease: effectiveness and value. Institute for Clinical and Economic Review; 2019. Available from: https://icer.org/assessment/cvd-additive-therapies-2019/. Accessed 22 Mar 2022.
  2. CADTH Canadian Drug Expert Committee Recommendation: Icosapent Ethyl (Vascepa—HLS Therapeutics Inc.): Indication: prevention of cardiovascular events in statin-treated patients. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020. Available from: http://www.ncbi.nlm.nih.gov/books/NBK566005/. Accessed 23 Jan 2022.
  3. Joint Formulary Committee. British national formulary 80. London: BMJ Publishing and the Royal Pharmaceutical Society; 2020.

Cited by

See all 20

Metadata

Authors
Michaeli, D. T., Michaeli, J. C., Boch, T., & Michaeli, T.
Affiliations
  • Heidelberg University (DE)
  • German Cancer Research Center (DE)
Corresponding author
Michaeli, Daniel Tobias
Venue
Clinical Drug Investigation
Published
2022-07-11
Volume
42
Issue
8
Pages
643-656
ISSN
  • 0114-2402 (ISSN-L)
  • 1173-2563
  • 1179-1918
OpenAlex
W4285077730
Cited by
20
References
44
Citations by year
2026: 2 · 2025: 8 · 2024: 7 · 2023: 3
FWCI
4.30
Type
journal article
Language
en
Open access
Licence
Locations
  • Clinical Drug Investigation (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Informationszentrum Lebenswissenschaften (ZB MED) (acceptedVersion, cc-by-nc)
Funders
Medizinische Fakultät Mannheim der Universität Heidelberg
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Keywords
icosapent ethyl, evolocumab, alirocumab, ezetimibe, fenofibrate, statin combination therapy, statin monotherapy, cost-effectiveness, major adverse cardiovascular events, dyslipidemia, omega-3 fatty acids, PCSK9 inhibitors, primary prevention of cardiovascular disease, secondary prevention of cardiovascular disease, quality-adjusted life years, National Health Service
MeSH terms
Ezetimibe, Proprotein Convertase 9, Cardiovascular Diseases, Cost-Benefit Analysis, Humans, Myocardial Infarction, Fenofibrate, State Medicine, Eicosapentaenoic Acid, Quality-Adjusted Life Years, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy. https://app.cochat.ai/papers/10.1007/s40261-022-01173-3
The paper
Michaeli, D. T., Michaeli, J. C., Boch, T., & Michaeli, T. (2022). Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy. Clinical Drug Investigation. https://doi.org/10.1007/s40261-022-01173-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.